Botox maker Galderma sees early boost from 'Ozempic face' trend as GLP-1 use climbs, CEO says
The aestetics company hope increased GLP-1 use will fuel demand for treatments addressing facial volume loss, sometimes dubbed "Ozempic face."
Overview
The aestetics company hope increased GLP-1 use will fuel demand for treatments addressing facial volume loss, sometimes dubbed "Ozempic face."
Source
Originally published at www.cnbc.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.